NEMRX Mutual Fund

NAV$28.60

Fund Essentials - as of Feb 28, 2026

Net Assets
$631,695
Expense Ratio
1.60%
Dividend Yield (Current)
-
Holdings
45
Inception Date
Jun 21, 2010
Fund Family
Neuberger Berman
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD-0.68%
1 Year+16.51%
3 Year+15.50%
5 Year+1.78%
10 Year+5.73%

Asset Allocation

Stocks: 95.69%
Cash: 4.31%

Price Chart (6M)

Loading chart data...

Top Holdings

View All →
TickerNameWeight
005930:KRSamsung Electronics Co. Ltd.4.52%
TRVXXState Street Institutional Treasury Money Market Fund4.31%
VIVT3:BVTelefonica Brasil Sa3.38%
PDDPinduoduo Inc - Adr3.36%
2330:TWTAIWAN SEMICONDUCTOR3.25%
Top 10 Concentration: 33.73%Report Date: Feb 28, 2026
Download all 45 holdings for NEMRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$0.14
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how NEMRX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

NEMRX Mutual Fund Overview

NEMRX Mutual Fund (Neuberger Berman Emerging Markets Equity Fund Classass R3) is managed by Neuberger Berman with $631,695 in net assets. NEMRX expense ratio is 1.60%, holding 45 positions across sectors including Unknown, Materials, Consumer Discretionary. Inception date: 2010-06-21.

NEMRX performance shows a YTD return of -0.68%. The 1-year return is 16.51% and the 5-year return is 1.78%.

NEMRX top holdings include Samsung Electronics Co. Ltd. (4.5%), State Street Institutional Treasury Money Market Fund (4.3%), Telefonica Brasil Sa (3.4%), Pinduoduo Inc - Adr (3.4%), TAIWAN SEMICONDUCTOR (3.3%). View all NEMRX holdings, sector breakdown, or dividend history.

NEMRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. NEMRX alternatives are available via the screener, along with tax-loss harvesting opportunities.